{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:15:05Z","timestamp":1784970905309,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted delivery of lysosomal enzymes to the endocytic compartment of human cells represents a transformative technology for treating a large family of lysosomal storage diseases (LSDs). Gaucher disease is one of the most common types of LSDs caused by mutations to the lysosomal \u03b2-glucocerebrosidase (GBA). Here, we describe a genetic strategy to produce engineered exosomes loaded with GBA in two different spatial configurations for targeted delivery to the endocytic compartment of recipient cells. By fusing human GBA to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demonstrate that the chimeric proteins were successfully integrated into exosomes which were secreted as extracellular vesicles (EVs) by producer cells. Isolation and molecular characterization of EVs confirmed that the fusion proteins were loaded onto exosomes without altering their surface markers, particle size or distribution. Further, enzyme-loaded exosomes\/EVs added to cultured medium were taken up by recipient cells. Further, the endocytosed exosomes\/EVs targeted to endocytic compartments exhibited a significant increase in GBA activity. Together, we have developed a novel method for targeting and delivery of lysosomal enzymes to their natural location: the endocytic compartment of recipient cells. Since exosomes\/EVs have an intrinsic ability to cross the blood-brain-barrier, our technology may provide a new approach to treat severe types of LSDs, including Gaucher disease with neurological complications.<\/jats:p>","DOI":"10.1038\/s41598-019-53844-5","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:02:41Z","timestamp":1574334161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles"],"prefix":"10.1038","volume":"9","author":[{"given":"Mai Anh","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"53844_CR1","doi-asserted-by":"crossref","unstructured":"Parenti, G., Andria, G. & Ballabio, A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med 66, 471\u2013486 (2015).","DOI":"10.1146\/annurev-med-122313-085916"},{"key":"53844_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","volume":"5","author":"AH Futerman","year":"2004","unstructured":"Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5, 554\u2013565 (2004).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"53844_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00439-006-0280-4","volume":"121","author":"M Beck","year":"2007","unstructured":"Beck, M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121, 1\u201322 (2007).","journal-title":"Hum Genet"},{"key":"53844_CR4","doi-asserted-by":"crossref","unstructured":"Parenti, G., Pignata, C., Vajro, P. & Salerno, M. New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 31, 11\u201320 (2013).","DOI":"10.3892\/ijmm.2012.1187"},{"key":"53844_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","volume":"1793","author":"A Ballabio","year":"2009","unstructured":"Ballabio, A. & Gieselmann, V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 1793, 684\u2013696 (2009).","journal-title":"Biochim Biophys Acta"},{"key":"53844_CR6","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa033277","volume":"351","author":"J Aharon-Peretz","year":"2004","unstructured":"Aharon-Peretz, J., Rosenbaum, H. & Gershoni-Baruch, R. Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med 351, 1972\u20131977 (2004).","journal-title":"N Engl J Med"},{"issue":"6","key":"53844_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/MOP.0b013e32834c20d9","volume":"23","author":"Robin H. Lachmann","year":"2011","unstructured":"Lachmann, R. H. Enzyme replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 23, 588\u2013593 (2011).\u00a0","journal-title":"Current Opinion in Pediatrics"},{"key":"53844_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10545-006-0239-6","volume":"29","author":"JE Wraith","year":"2006","unstructured":"Wraith, J. E. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis 29, 442\u2013447 (2006).","journal-title":"J Inherit Metab Dis"},{"key":"53844_CR9","doi-asserted-by":"crossref","unstructured":"Wyatt, K. et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16, 1\u2013543 (2012).","DOI":"10.3310\/hta16390"},{"key":"53844_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med 324, 1464\u20131470 (1991).","journal-title":"N Engl J Med"},{"key":"53844_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","volume":"87","author":"NW Barton","year":"1990","unstructured":"Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M. & Brady, R. O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87, 1913\u20131916 (1990).","journal-title":"Proc Natl Acad Sci USA"},{"key":"53844_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis, E. D. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344, 182\u2013188 (2001).","journal-title":"N Engl J Med"},{"key":"53844_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med 345, 9\u201316 (2001).","journal-title":"N Engl J Med"},{"key":"53844_CR14","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"53844_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Van den Hout","year":"2000","unstructured":"Van den Hout, H. et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356, 397\u2013398 (2000).","journal-title":"Lancet"},{"key":"53844_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz, P. et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148, 533\u2013539 (2006).","journal-title":"J Pediatr"},{"key":"53844_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","volume":"57","author":"RO Brady","year":"2006","unstructured":"Brady, R. O. Enzyme replacement for lysosomal diseases. Annu Rev Med 57, 283\u2013296 (2006).","journal-title":"Annu Rev Med"},{"key":"53844_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1067\/mpd.2001.112171","volume":"138","author":"G Altarescu","year":"2001","unstructured":"Altarescu, G. et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease. J Pediatr 138, 539\u2013547 (2001).","journal-title":"J Pediatr"},{"key":"53844_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","volume":"122","author":"Maurizio Scarpa","year":"2017","unstructured":"Scarpa, M. et al. Treatment of brain disease in the mucopolysaccharidoses. Mol Genet Metab 122S, 25\u201334 (2017).","journal-title":"Molecular Genetics and Metabolism"},{"key":"53844_CR20","doi-asserted-by":"crossref","unstructured":"Bellettato, C. M. & Scarpa, M. Possible strategies to cross the blood-brain barrier. Ital J Pediatr 44, 131 (2018).","DOI":"10.1186\/s13052-018-0563-0"},{"key":"53844_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nrm3335","volume":"13","author":"M Mittelbrunn","year":"2012","unstructured":"Mittelbrunn, M. & Sanchez-Madrid, F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol 13, 328\u2013335 (2012).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"53844_CR22","doi-asserted-by":"crossref","unstructured":"Thery, C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep 3, 15 (2011).","DOI":"10.3410\/B3-15"},{"key":"53844_CR23","doi-asserted-by":"crossref","unstructured":"Record, M., Carayon, K., Poirot, M. & Silvente-Poirot, S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta 1841, 108\u2013120 (2014).","DOI":"10.1016\/j.bbalip.2013.10.004"},{"key":"53844_CR24","doi-asserted-by":"crossref","unstructured":"Choi, D. S., Kim, D. K., Kim, Y. K. & Gho, Y. S. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 13, 1554\u20131571 (2013).","DOI":"10.1002\/pmic.201200329"},{"key":"53844_CR25","doi-asserted-by":"crossref","unstructured":"EL Andaloussi, S., Mager, I., Breakefield, X. O. & Wood, M. J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12, 347\u2013357 (2013).","DOI":"10.1038\/nrd3978"},{"key":"53844_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2009","unstructured":"Kumari, A., Yadav, S. K. & Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75, 1\u201318 (2009).","journal-title":"Colloids Surf B Biointerfaces"},{"key":"53844_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"G Sahay","year":"2013","unstructured":"Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31, 653\u2013658 (2013).","journal-title":"Nat Biotechnol"},{"key":"53844_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29, 341\u2013345 (2011).","journal-title":"Nat Biotechnol"},{"key":"53844_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"53844_CR30","doi-asserted-by":"crossref","unstructured":"Guo, S. et al. Intranasal Delivery of Mesenchymal Stem Cell Derived Exosomes Loaded with Phosphatase and Tensin Homolog siRNA Repairs Complete Spinal Cord Injury. ACS Nano (2019).","DOI":"10.1021\/acsnano.9b01892"},{"key":"53844_CR31","doi-asserted-by":"crossref","unstructured":"Gorabi, A. M. et al. The Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Treatment of Neurodegenerative Diseases. Mol Neurobiol (2019).","DOI":"10.1007\/s12035-019-01663-0"},{"key":"53844_CR32","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.2147\/IJN.S196975","volume":"14","author":"NC Duong","year":"2019","unstructured":"Duong, N. C. et al. exosomes as a novel biologic reagent to antognize inflammation. International Journal of Nanomedicine 14, 3413\u20133425 (2019).","journal-title":"International Journal of Nanomedicine"},{"key":"53844_CR33","doi-asserted-by":"crossref","unstructured":"Kim, I. K., Kim, S. H., Choi, S. M., Youn, B. S. & Kim, H. S. Extracellular Vesicles as Drug Delivery Vehicles for Rheumatoid Arthritis. Curr Stem Cell Res Ther 11, 329\u2013342 (2016).\u00a0","DOI":"10.2174\/1574888X11666151203223251"},{"key":"53844_CR34","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.ymgme.2017.12.060","volume":"123","author":"K Choi","year":"2017","unstructured":"Choi, K., Choi, H., Yim, N., Ryu, S. W. & Choi, C. Exosome-based delivery of glucocerebrosidase lysosomal enzyme for treatment of Gaucher disease. Molecular Genetics and Metabolism. 123, S31\u2013S32 (2017).","journal-title":"Molecular Genetics and Metabolism."},{"key":"53844_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska, K. S., LaMarca, M. E., Scott, C. R. & Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29, 567\u2013583 (2008).","journal-title":"Hum Mutat"},{"key":"53844_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski, G. A. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet 372, 1263\u20131271 (2008).","journal-title":"Lancet"},{"key":"53844_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbrc.2016.02.058","volume":"472","author":"Z Stickney","year":"2016","unstructured":"Stickney, Z., Losacco, J., McDevitt, S., Zhang, Z. & Lu, B. Development of exosome surface display technology in living human cells. Biochem Biophys Res Commun 472, 53\u201359 (2016).","journal-title":"Biochem Biophys Res Commun"},{"key":"53844_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ab.2006.04.046","volume":"356","author":"M Hampf","year":"2006","unstructured":"Hampf, M. & Gossen, M. A protocol for combined Photinus and Renilla luciferase quantification compatible with protein assays. Anal Biochem 356, 94\u201399 (2006).","journal-title":"Anal Biochem"},{"key":"53844_CR39","doi-asserted-by":"crossref","unstructured":"Peterson, M. F., Otoc, N., Sethi, J. K., Gupta, A. & Antes, T. J. Integrated systems for exosome investigation. Methods 87, 31\u201345 (2015).","DOI":"10.1016\/j.ymeth.2015.04.015"},{"key":"53844_CR40","doi-asserted-by":"crossref","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","DOI":"10.1016\/j.cell.2011.06.001"},{"key":"53844_CR41","doi-asserted-by":"crossref","unstructured":"Yun, S. P. et al. alpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener 13, 1 (2018).","DOI":"10.1186\/s13024-017-0233-5"},{"key":"53844_CR42","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2147\/IJN.S133430","volume":"12","author":"C Meyer","year":"2017","unstructured":"Meyer, C. et al. Pseudotyping exosomes for enhanced protein delivery in mammalian cells. Int J Nanomedicine 12, 3153\u20133170 (2017).","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"53844_CR43","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-17-0827","volume":"17","author":"Jing-Hung Wang","year":"2018","unstructured":"Wang, J. H. et al. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. Mol Cancer Ther 17, 1133\u20131142 (2018).","journal-title":"Molecular Cancer Therapeutics"},{"key":"53844_CR44","doi-asserted-by":"crossref","first-page":"14319","DOI":"10.1016\/S0021-9258(17)38720-3","volume":"260","author":"AH Erickson","year":"1985","unstructured":"Erickson, A. H., Ginns, E. I. & Barranger, J. A. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J Biol Chem 260, 14319\u201314324 (1985).","journal-title":"J Biol Chem"},{"key":"53844_CR45","doi-asserted-by":"crossref","first-page":"14861","DOI":"10.1016\/S0021-9258(18)82412-7","volume":"268","author":"A Berg-Fussman","year":"1993","unstructured":"Berg-Fussman, A., Grace, M. E., Ioannou, Y. & Grabowski, G. A. Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem 268, 14861\u201314866 (1993).","journal-title":"J Biol Chem"},{"key":"53844_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5772\/61186","volume":"4","author":"KJ McKelvey","year":"2015","unstructured":"McKelvey, K. J., Powell, K. L., Ashton, A. W., Morris, J. M. & McCracken, S. A. Exosomes: Mechanisms of Uptake. J Circ Biomark 4, 7 (2015).","journal-title":"J Circ Biomark"},{"key":"53844_CR47","doi-asserted-by":"crossref","unstructured":"Ha, D., Yang, N. & Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 6, 287\u2013296 (2016).","DOI":"10.1016\/j.apsb.2016.02.001"},{"issue":"6","key":"53844_CR48","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ymthe.2017.03.030","volume":"25","author":"Ulrich Sterzenbach","year":"2017","unstructured":"Sterzenbach, U. et al. Engineered Exosomes as Vehicles for Biologically Active Proteins. Mol Ther 25, 1269\u20131278 (2017).","journal-title":"Molecular Therapy"},{"key":"53844_CR49","doi-asserted-by":"crossref","unstructured":"Shahabipour, F., Banach, M. & Sahebkar, A. Exosomes as nanocarriers for siRNA delivery: paradigms and challenges. Arch Med Sci 12, 1324\u20131326 (2016).","DOI":"10.5114\/aoms.2016.62911"},{"key":"53844_CR50","doi-asserted-by":"crossref","unstructured":"Riazifar, M., Pone, E.J., Lotvall, J. & Zhao, W. Stem Cell Extracellular Vesicles: Extended Messages of Regeneration. Annu Rev Pharmacol Toxicol 57, 125\u2013154 (2017).","DOI":"10.1146\/annurev-pharmtox-061616-030146"},{"key":"53844_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12277","volume":"7","author":"N Yim","year":"2016","unstructured":"Yim, N. et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun 7, 12277 (2016).","journal-title":"Nat Commun"},{"key":"53844_CR52","doi-asserted-by":"crossref","unstructured":"Antes, T. J. et al. Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display. J Nanobiotechnology 16, 61 (2018).","DOI":"10.1186\/s12951-018-0388-4"},{"key":"53844_CR53","doi-asserted-by":"crossref","unstructured":"Hung, M. E. & Leonard, J. N. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem 290, 8166\u20138172 (2015).","DOI":"10.1074\/jbc.M114.621383"},{"key":"53844_CR54","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/S0021-9258(17)42166-1","volume":"269","author":"ME Grace","year":"1994","unstructured":"Grace, M. E., Newman, K. M., Scheinker, V., Berg-Fussman, A. & Grabowski, G. A. Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J Biol Chem 269, 2283\u20132291 (1994).","journal-title":"J Biol Chem"},{"key":"53844_CR55","doi-asserted-by":"crossref","unstructured":"Smith, L., Mullin, S. & Schapira, A. H. V. Insights into the structural biology of Gaucher disease. Exp Neurol 298, 180\u2013190 (2017).","DOI":"10.1016\/j.expneurol.2017.09.010"},{"key":"53844_CR56","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek, D. et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131, 770\u2013783 (2007).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53844-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:16:52Z","timestamp":1671293812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53844-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53844"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53844-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"27 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Santa Clara University has filed patents (pending) related to work presented in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17274"}}